• China’s NMPA cleared a supplemental filing for Boluojia (denosumab) 120 mg to treat bone metastases from solid tumors or multiple myeloma.
• The label expansion targets prevention of skeletal-related events, a larger oncology use than its May 2024 China approval in giant cell tumor of bone.
• Boluojia is a biosimilar of Amgen’s Xgeva; Xgeva logged about USD 2.08 billion in 2025 sales, including about USD 306 million in China.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260526-12170395), on May 26, 2026, and is solely responsible for the information contained therein.